As NMPA approves IND registration for frontier immunotherapies, more and more innovative therapies are stepping from laboratory to clinic, from academia to industrialization. However, it also brings new challenges:

Facing the translation and processing challenges of frontier therapies, IGC 2019 (3rd World-China Immunotherapy & Gene Therapy Congress) will, from three aspects of drug discovery, clinical translation and industrialization, three forums and six sections, interpret domestic and foreign immunotherapy policies and regulatory trends; discuss the new research, new technology and new product breakthroughs of cellular immunotherapy, large and small molecular immunotherapy, therapeutic cancer vaccine and oncolytic virus immunogene therapy at home and abroad; promote in-depth exchanges and cooperation between industry, university, research and medicine, and accelerate the industrial transformation of immunotherapy and gene therapy.